Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

1998 • 19,638 citations

Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.

1974 • 1,451 citations

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.

1998 • 1,338 citations

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

2002 • 1,295 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

2001 • 881 citations

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

1992 • 858 citations

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo.

1995 • 741 citations

PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES

1997 • 701 citations

World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects

1997 • 634 citations

A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans

2001 • 590 citations

Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers

2002 • 553 citations

Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

1999 • 516 citations

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men

2002 • 498 citations

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

1996 • 460 citations

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

1999 • 454 citations

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes

2003 • 358 citations

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

1999 • 335 citations

Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men

1998 • 298 citations

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1996 • 291 citations

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM

1996 • 286 citations

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single-Dose of NN2211, a Long-Acting Glucagon-Like Peptide 1 Derivative, in Healthy Male Subjects

2002 • 286 citations

Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes

2002 • 269 citations

Ileal release of glucagon-like peptide-1 (GLP-1)

1995 • 216 citations

Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

1995 • 199 citations

Hyperproinsulinemia and Amyloid in NIDDM: Clues to Etiology of Islet β-Cell Dysfunction?

1989 • 186 citations

Glucagon-Like Peptide-1 Infusion Must Be Maintained for 24 h/day to Obtain Acceptable Glycemia in Type 2 Diabetic Patients Who Are Poorly Controlled on Sulphonylurea Treatment

2001 • 172 citations

Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?

2001 • 115 citations

Immune Responses to Insulin Aspart and Biphasic Insulin Aspart in People With Type 1 and Type 2 Diabetes

2002 • 112 citations

A Dose-Response Study of Glimepiride in Patients With NIDDM Who Have Previously Received Sulfonylurea Agents

1996 • 95 citations

Hyperproinsulinemia and amyloid in NIDDM. Clues to etiology of islet beta-cell dysfunction?

1989 • 61 citations

GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes: Selection of NN2211 for clinical development

2001 • 34 citations

Guide to Diagnosis and Classification of Diabetes Meliitus and Other Categories of Glucose Intolerance

1997 • 12 citations

Cited By (0)

Loading...